Trinity College
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private, Subsidiary
- Established
- 1823-01-01
- Employees
- 680
- Market Cap
- -
Mixed Results for Adjuvant Therapies in Solid Tumors: Key Takeaways From ESMO 2024
• The ENGOT-en11/GOG-3053/KEYNOTE-B21 trial showed adjuvant pembrolizumab plus chemotherapy did not improve disease-free survival in all high-risk endometrial cancer patients, but significantly improved outcomes in dMMR subgroup.
• Updated IMbrave050 analysis revealed that the initial recurrence-free survival benefit of adjuvant atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma was not sustained over extended follow-up.
• The CCTG BR.31 trial indicated adjuvant durvalumab did not significantly improve disease-free survival in early-stage NSCLC, regardless of PD-L1 expression levels.
© Copyright 2025. All Rights Reserved by MedPath